CHRONIC HEEL PAIN: RESULTS OF FDA SHOCKWAVE STUDY

Extracorporeal shock wave treatment of intractable tennis elbow. Results of a pilot study
17 juin 2013
Surgical and nonsurgical treatment for athletic tendinopathy
17 juin 2013

CHRONIC HEEL PAIN: RESULTS OF FDA SHOCKWAVE STUDY

Authors:

J.A. Ogden, R.Alvarez, R.Levitt, G.L.Cross

Institution:

Atlanta Medical Center

 

The objective of this multicenter, randomized,   placebo-controlled, FDA approved clinical study was to determine the safety   and effectivencas of ESW (Extracorporeal Shockwave) treatment for chronic heel   pain syndrom. The study was designed to demonstrate the initial success/failure   of treatment results at 12 weeks post-treatment, and to provide sufficient preliminary   safety and effectiveness data related to repeat ESW treatment in patients who   failed to respond to initial treatment.

Between April 1998 and November 1999, 302   patients were treated for chronic heel pain syndrome using the OssaTron ESW   System. 260 patients were randomizing to either active or placebo ESW treatment,   an 42 patients were not randomized to ESW for investigator training purposes.   The study was conducted at seven institutions throughout the U.S. For this study   chronic heel pain syndrome was defined as symptoms of moderate to severe pain   in this affected heel at the origin of the plantar fascia that had persisted   for at least six months prior to study enrollment. Mean duration of symptoms   for the subjects randomized to active treatment was 26 years, range 6 months   to 13 years, and for subjects randomized to placebo treatment 29 years, range   6 months to 18 years. A subject had to have a pain score of 5.0 or greater on   10cm VAS based upon investigator assessment and must have failed 3 prior courses   of non-operative treatment. Patients who failed to improve following the first   procedure were aligible for retreatment with a nonrandomized ESW treatment.

 

Evaluations were obtained pre-treatment and   4,8 and 12 weeks post-treatment. An initial success/fail status was assigned   based on findings at 12 weeks post-treatment. It was felt that the status assignment   at the 12 weeks interval could help differnetiate improvement due to spontaneous   healing rather than treatment effect. Subjects have continued follow-up to,   determine durability of results at one year.

 

Study findings for the 234 randomized patients   followed to 12 weeks showed a clinically as well as statistically significant   difference in the treatment versus placebo groups (p-0.008). The average baseline   Visual Analog Scale (VAS) score for Investigator Assessment improved from 7.7   (median 7.8) to 3.1(median 1.9); the average baseline Visual Analog Scale (VAS)   score for Patient Self Assessment improved from 8.0 (median 8.1) to 3.4 (median   2.6). By grouping patients randomized to active treatment, nonrandomized patients,   a small subset of active treatment patients who failed to ….success criteria   following a primary OssaTron ESW treatment and elected to have a repeat treatment   and subsequently treated placebo patients. 76% of all treated patients had good   to excellent results, while 24% had poor or fai results. In a subset of patients   undergoing repeat treatment following and unsatisfactory primary treatment,   the success rate was 90,5% based on the Investigators Assessment.

 

This study showed that the OssaTron ESW System   is a safe and effective non-invasive method for treating chronic, recalcitrant   heel pain syndrome. The complication rate was low. Complications (usually petechiae)   were mild and transient in nature.

Comments are closed.